Comparing the current results to its competitors, Blue Line Protection Group Inc reported Revenue decrease in the 4 quarter 2024 year on year by -28.04 %, despite the revenue increase by the most of its competitors of 15.65 %, recorded in the same quarter.
Blue Line Protection Group Inc Net Income in the 4 quarter 2024 grew year on year by 580.14%, while most of its competitors have experienced a contraction in net income by -5.75 %.
Publicly Traded Peers of Blue Line Protection Group Inc
Vertex Pharmaceuticals Inc Share Performance
-3.49%
30 Days
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
